Browse the evidence

Surgical removal of adipose tissue and specific genetic modifications (e.g., deletion of diacylglycerol acyltransferase 1) extend lifespan in rodents.

In rodents, removing fat or modifying specific fat-synthesis genes extends life. This highlights the critical role of adipose tissue in aging. For humans, this suggests that managing body fat levels is crucial for healthspan, though surgical removal is not a viable longevity strategy.

Exposure to Endocrine-Disrupting Chemicals (EDCs) such as Bisphenol A (BPA) and Diethylstilbestrol (DES) during fetal development can cause transgenerational epigenetic changes leading to increased risks of cancer, obesity, and reproductive disorders in offspring and subsequent generations.

Minimize exposure to endocrine disruptors like BPA (found in some plastics) and DES-like compounds. Use glass or stainless steel containers for food storage, avoid heating food in plastic, and choose fresh foods over canned when possible to reduce intake of these chemicals, especially during pregnancy.

The metabolic effects of central ghrelin on adipose tissue are mediated by the sympathetic nervous system, as evidenced by the lack of metabolic response in mice lacking beta-adrenergic receptors.

The brain's command to store fat via ghrelin is sent through the sympathetic nervous system. Disrupting this pathway (as seen in specific genetic knockouts) blocks the fat-storage signal, highlighting the nervous system's role in hormonal fat regulation.

Endogenous satiation signals (like CCK) are subservient to long-term adiposity signals (leptin/insulin) and cannot cause long-term weight loss in free-feeding animals because they compensate by eating more frequently.

Your body's natural 'fullness' signals (like CCK) are not strong enough to keep you thin if you are genetically prone to obesity, because your body will just make you eat more often to compensate. This is why willpower alone often fails.

High-dose resveratrol supplementation (1500 mg/day) for 4 weeks produces no significant improvement in insulin sensitivity, substrate metabolism, blood pressure, or body composition in obese men.

Taking 1500 mg of resveratrol daily for a month will not improve your insulin sensitivity, lower your blood pressure, or change your body composition if you are obese. The supplement does not work for these metabolic goals in humans, despite what animal studies suggest.

Maternal exposure to high-fat diets during pregnancy programs fetal hypothalamic development to predispose offspring to obesity and metabolic complications, independent of maternal obesity.

A mother's diet during pregnancy, specifically high-fat intake, can program her child's brain to crave more food and store fat more easily. This happens even if the mother doesn't become obese. Pregnant women should prioritize balanced, low-fat diets to protect their child's long-term metabolic health.

DPP-IV inhibitors (e.g., sitagliptin) lack strong clinical evidence for improving NAFLD/NASH histology and may be ineffective in controlled trials, despite promising animal model data.

Do not rely on DPP-IV inhibitors (like sitagliptin) to treat your liver disease. While they help with blood sugar, controlled studies show they do not significantly improve liver fat or inflammation in NAFLD/NASH patients.

Pharmacological inhibition of mTOR via rapamycin extends lifespan across multiple model organisms, including yeast, nematodes, fruit flies, and mice.

This paper establishes that inhibiting the mTOR pathway, specifically via rapamycin, extends lifespan in various animals. While this is a key finding in longevity research, the paper notes that translating this to humans requires understanding the complex interplay with nutrient sensing and potential side effects, as rapamycin is an immunosuppressant.

In the context of preexisting severe obesity and adipose tissue dysfunction (ob/ob mice), blocking VEGF-A signaling reduces body weight gain, improves insulin sensitivity, and decreases inflammation by inducing apoptosis in dysfunctional, hypoxic adipocytes.

This study suggests that treatments targeting blood vessels in fat might help people with severe, established obesity by reducing the number of unhealthy, inflamed fat cells. This is a complex medical intervention and not a lifestyle strategy.

In utero exposure to famine or severe nutritional restriction increases the adult risk of hypertension, type 2 diabetes, and obesity, with risk magnitude dependent on the specific gestational timing of exposure.

If you were born to a mother who experienced severe food scarcity, your body may be biologically primed to store fat and regulate blood sugar differently than average. This is not a character flaw. Focus on consistent, moderate nutritional quality and regular physical activity to support your metabolic health, rather than extreme restrictive diets which may trigger further metabolic adaptation.

Non-coding RNAs (miRNAs, lncRNAs, circRNAs) regulate gene expression in metabolic diseases and serve as diagnostic/prognostic biomarkers and potential therapeutic targets.

Research into non-coding RNAs is leading to new diagnostic tools and potential drugs that can silence or enhance specific genes involved in metabolism, offering hope for treating conditions like obesity and diabetes.

Exogenous reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2), accelerate adipocyte differentiation and mitotic clonal expansion by enhancing the DNA binding activity of the transcription factor C/EBPalpha.

This research explains the biological mechanism of how fat cells form, highlighting that a certain level of oxidative stress (ROS) is required for pre-fat cells to multiply and mature. It does not suggest that you should consume hydrogen peroxide or seek oxidative stress. However, it implies that excessive antioxidant supplementation might theoretically interfere with normal fat cell differentiation processes in the body, although this is observed in cell cultures, not necessarily in whole human physiology.

Ovariectomy leads to hepatic steatosis (fatty liver) driven by upregulation of PPAR-gamma and lipogenic genes, independent of dietary fat intake.

Menopause increases the risk of fatty liver disease through hormonal changes that activate fat-producing genes in the liver, even without eating more fat.

There is no consistent causal evidence that higher BMI or Type 2 Diabetes causes changes in chronotype or sleep duration, nor that chronotype or sleep duration causally affect BMI or Type 2 Diabetes, despite observed genetic correlations.

While poor sleep and obesity are linked, this study suggests that one does not necessarily cause the other. You may need to address both sleep hygiene and metabolic health independently, as they might share common genetic roots rather than a direct cause-and-effect relationship.

Blockade of central melanocortin receptors decreases glucose utilization in skeletal muscle and brown adipose tissue while increasing glucose uptake in white adipose tissue.

Your brain directs glucose to different tissues based on hormonal signals. When these signals are disrupted, your muscles may become less efficient at using glucose, while your fat cells become more efficient at taking it up for storage.

Glucocorticoids promote adipocyte differentiation and increase adipocyte size, particularly in visceral and subcutaneous depots, contributing to fat redistribution in Cushing's syndrome.

Chronic steroid exposure changes how fat cells grow and multiply, especially in the belly. This is not just about eating more; the hormones actively encourage fat storage cells to form and expand in specific areas.

Dysbiosis in NASH, specifically decreased abundance of Clostridium leptum and Bacteroidetes, is associated with altered bile acid homeostasis, leading to higher levels of unconjugated primary bile acids.

Your gut bacteria play a direct role in liver health. In NASH, specific beneficial bacteria (like C. leptum) are depleted, which leads to higher levels of potentially toxic primary bile acids in the gut. This suggests that gut health interventions should target these specific microbial deficits to help normalize bile acid metabolism.

Inhibition of mTOR by rapamycin exacerbates metabolic dysfunction in type 2 diabetes by preventing beta-cell adaptation, inducing beta-cell apoptosis, and increasing insulin resistance.

Do not use mTOR inhibitors like rapamycin to treat type 2 diabetes. While these drugs may improve insulin sensitivity in muscle, they destroy pancreatic beta-cells and prevent the pancreas from adapting to high blood sugar, leading to severe worsening of diabetes.

In utero exposure to maternal hyperglycemia (gestational diabetes or elevated glucose levels) independently increases the risk of abnormal glucose tolerance, obesity, and higher blood pressure in offspring by age 7, independent of maternal pre-pregnancy BMI, birth weight, or childhood obesity.

If a mother has gestational diabetes or elevated blood sugar during pregnancy, her child is at a higher risk for metabolic issues like obesity and glucose intolerance by age 7, regardless of the child's birth weight. This risk is biological and programmed in utero. Parents should be aware of this increased risk and prioritize regular metabolic health monitoring (blood pressure, glucose, weight) for their children, especially if there is a family history of diabetes.

Genetic overexpression of Wnt10b in adipose tissue inhibits the development of both white and brown adipose tissue, resulting in reduced total body fat and resistance to diet-induced obesity without causing lipodystrophic diabetes.

This research highlights a specific genetic pathway (Wnt10b) that, when active, prevents fat storage and improves metabolic health. While you cannot genetically engineer your body to overexpress Wnt10b, the findings suggest that maintaining healthy insulin sensitivity and avoiding excessive fat accumulation can prevent the metabolic complications often associated with obesity. Focus on sustainable lifestyle habits rather than seeking quick fixes, as metabolic health is preserved even with lower fat mass if other factors are managed.

Central nervous system (CNS) leptin signaling is sufficient to regulate body weight, feeding, energy expenditure, and glucose metabolism, independent of peripheral leptin action.

Leptin works primarily in the brain, not directly on fat or muscle tissue, to control metabolism and blood sugar.

PGC-1α regulates ANT1 protein content, which influences submaximal ADP-stimulated respiration and intrinsic mitochondrial function.

Maintaining PGC-1α levels through exercise may support efficient energy exchange in mitochondria, potentially improving metabolic efficiency.

Metformin extends lifespan in C. elegans by inducing mitohormesis, a process where partial inhibition of mitochondrial complex I increases ROS production, which is translated into a longevity signal by the peroxiredoxin PRDX-2.

This research suggests that the longevity benefits of metformin in worms are driven by a specific stress-response pathway (mitohormesis) involving ROS and the protein PRDX-2. While this provides a mechanistic explanation for metformin's effects in a model organism, it does not directly translate to a human dosing protocol or guarantee similar lifespan extension in humans without further clinical validation.

Fasting-induced PGC-1α activation of the nuclear receptor FXR reduces plasma triglyceride levels in wild-type mice, a mechanism absent in FXR-null mice.

Fasting is a powerful tool for lowering triglycerides, but its effectiveness relies on a functional FXR pathway. If you have genetic variations affecting this receptor, fasting might not lower your triglycerides and could potentially raise them. This mechanism highlights why individual responses to fasting vary.